About Us: Overview

TRANSLATING SCIENCE TO IMPROVE PATIENTS’ LIVES
Aditum Bio is a new model of biotech venture capital, uniquely positioned to rapidly translate scientific discoveries into innovative new medicines.
 

NEW MODEL OF VENTURE CAPITAL

AGILE, INVENTIVE, RESPONSIVE

Aditum Bio brings together unmatched scientific and domain expertise with agile operational capabilities. Our unique investment and operating model enables rapid company formation, planning, and execution to advance novel drug candidates into the clinic and speed their delivery to the patients in need.

Aditum Bio New Model of Venute Capital.jpg

PROVEN INDUSTRY LEADERSHIP AND SCIENTIFIC EXPERTISE

Launched by former Novartis CEO, Joe Jimenez, and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, the experience of our founding executive team provides Aditum Bio with a unique lens for identifying and selecting innovative drug candidates with unrecognized potential.

Aditum Bio Faster Returns for Investors.jpg

BETTER OUTCOMES FOR PATIENTS. FASTER RETURNS FOR INVESTORS.

By singularly focusing on the translation phase of drug development, Aditum Bio efficiently identifies and develops potentially first- and best-in-class therapies for a broad array of diseases – empowering our ability to reach more patients and creating faster return for its capital investments.